The Gov't. will never allow Amgen to buy a major competitor of Epogen. AMGN is already in trouble with many department's having paid the biggest fine ever last year for marketing a verboten product.
Some members of Congress have now picked on Amgen for further review of recent allowances within the latest health care bills - Rep Peter Welch of Vermont being a determined one.
Some other pharmacutical could very well be a buyer of this one.